Adamax

N-Acetyl Semax Analog with Adamantyl Group — Synthetic Nootropic Neuropeptide / ACTH(4–10) Analog / Advanced Semax Derivative
Intended Audience: Licensed physicians and advanced practitioners integrating neurotrophic peptides, cognitive modulators, and central metabolic regulators into clinical practice. This guide is particularly suited for those managing patients with cognitive fatigue, neuroendocrine dysregulation, stress-related metabolic resistance, or individuals pursuing high-performance cognitive enhancement alongside body composition and metabolic health goals.

1. Clinical Overview of Adamax

Molecule:
Adamax (N-Acetyl Semax analog with adamantyl group)

Classification:
Synthetic nootropic neuropeptide • ACTH(4–10) analog • Advanced Semax derivative • Cognitive optimizer

Clinical Orientation

Adamax is an advanced derivative of the well-studied peptide Semax, structurally enhanced with an adamantyl group and N-terminal acetylation to improve central nervous system penetration and metabolic stability. Designed to elevate neuroplasticity, improve focus, and protect against oxidative brain injury, Adamax is considered a high-potency cognitive optimizer with promising nootropic and neuroprotective effects.

Key Advantages Over Semax:

Research-Supported Applications

Research and practitioner reports suggest Adamax may be used to support:

2. Mechanism of Action

Adamax exerts its effects through multiple neurotrophic and neuromodulatory pathways:

Primary Mechanisms:

Neurotrophic Cascade

By activating BDNF and related growth factors, Adamax supports:

3. Potential Clinical Benefits

Cognitive Enhancement

Stress Resilience & Mood

Neuroprotection

4. Route of Administration

Route Preference Notes
Intranasal Preferred Direct CNS targeting, rapid onset, bypasses BBB
Subcutaneous Alternative Systemic delivery, reliable absorption

5. Dosing Guidelines

Intranasal Protocol (Preferred)

Standard Intranasal Dosing:

Subcutaneous Protocol (Alternative)

Reconstitution & Dosing:
💡 Clinical Tip: Most practitioners find intranasal administration provides faster onset and more pronounced cognitive effects due to direct CNS delivery. Reserve subcutaneous for patients who cannot tolerate intranasal or when systemic effects are preferred.

6. Treatment Archetypes — Who Is This For?

High-Performance Cognitive Optimization

Students, executives, creatives, and professionals requiring sustained focus and mental clarity.

Protocol: 200 mcg intranasal AM, optional 100 mcg midday microdose

Post-TBI or Neurologic Insult Recovery

Patients recovering from traumatic brain injury, stroke, or neuroinflammatory conditions.

Protocol: 200–400 mcg daily (divided doses), combined with SS-31 and NAD+

Age-Related Cognitive Support

Memory and cognition support in aging populations experiencing mild cognitive decline.

Protocol: 200 mcg intranasal daily, cycling 5/2, with Pinealon for genomic stability

Neurodiverse Focus Enhancement

Focus and learning enhancement in neurodiverse profiles (ADHD-like presentations) seeking non-stimulant options.

Protocol: Start 100 mcg, titrate to response, combine with Selank for mood balance

Nootropic & Neuroregenerative Programs

Adjunctive support in comprehensive cognitive optimization and biohacking protocols.

Protocol: Stack with Selank, Pinealon, NAD+, and mitochondrial support agents

7. Synergistic Stacking Options

Adamax + Selank

Mood balancing and executive function synergy; anxiolytic + cognitive enhancement

Adamax + Pinealon

Anti-aging and genomic neurostability; epigenetic brain health support

Adamax + SS-31

Mitochondrial support and neuroinflammation reduction; cellular energy optimization

Adamax + NAD+

Energy metabolism and neuroprotective enhancement; sirtuin activation

Adamax + DSIP

Sleep optimization adjunct to support cognitive recovery and memory consolidation

Adamax + Dihexa

Synergistic neuroplasticity and memory enhancement; advanced cognitive stack

8. Contraindications & Cautions

Contraindications:
Use With Caution:

9. Monitoring Parameters

Subjective Monitoring

Optional Objective Measures

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

Adamax and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner. Practitioners must exercise independent clinical judgment and assess each patient's individual medical needs, risks, comorbidities, and contraindications prior to implementing any protocol.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions. Any compounding, reconstitution, or administration of peptides must follow appropriate sterile technique and must only be performed by individuals lawfully authorized to handle such materials.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — Adamax Clinical Reference Guide

1. Panchenko, S.A., et al. (2017). Neuroprotective and Nootropic Properties of ACTH Analog Semax and Its Derivatives. Neuroscience and Behavioral Physiology, 47(5), 567–575.
2. Myasoedov, N.F., et al. (2019). Peptide-Based Neurotrophic Agents: Advances in Semax and Selank Development. Neurochemical Journal, 13(4), 261–271.
3. Jay Campbell. (2025). Adamax and P21: The Next Evolution in Cognitive Peptides. Optimized Biohacking Review, accessed March 2025.
4. Behemoth Labz. (2025). Adamax Research Profile. Available at: https://www.behemothlabz.com
5. Cytokine & Growth Factor Reviews. (2017). Mechanisms of BDNF Modulation via Semax.
6. PatSnap Synapse. (2024). Peptide Derivative Analysis – N-Acetyl Semax vs. Adamax. Available at: https://www.patsnap.com
7. Peptide Protocol Portal Internal Monograph Archive. (2025).